CY1107467T1 - Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων - Google Patents

Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων

Info

Publication number
CY1107467T1
CY1107467T1 CY20061100815T CY061100815T CY1107467T1 CY 1107467 T1 CY1107467 T1 CY 1107467T1 CY 20061100815 T CY20061100815 T CY 20061100815T CY 061100815 T CY061100815 T CY 061100815T CY 1107467 T1 CY1107467 T1 CY 1107467T1
Authority
CY
Cyprus
Prior art keywords
oxogenous
hydro
prevention
treatment
digestive disorders
Prior art date
Application number
CY20061100815T
Other languages
English (en)
Inventor
Michel Renaud
Annick Bernalier
Original Assignee
Institut National De La Recherche Agronomique (Inra)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107467(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institut National De La Recherche Agronomique (Inra) filed Critical Institut National De La Recherche Agronomique (Inra)
Publication of CY1107467T1 publication Critical patent/CY1107467T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/742Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)

Abstract

Η εφεύρεση αφορά τη χρήση μη παθογόνων βακτηριακών οξεογόνων υδρογονοτρόφων στελεχών για την παρασκευή μίας συνθέσεως προοριζόμενης για την αγωγή ή την πρόληψη των γαστρεντερικών διαταραχών των σχετιζόμενων με την παραγωγή πεπτικών αερίων και/ή για τη ρύθμιση της μικροβιακής ισορροπίας του πεπτικού οικοσυστήματος στα θηλαστικά. Η εφεύρεση αφορά επίσης τις εv λόγω φαρμακευτικές ή διατροφικές συνθέσεις, καθώς και μεθόδους παρακολουθήσεως και παρασκευής των εν λόγω στελεχών.
CY20061100815T 2000-05-11 2006-06-19 Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων CY1107467T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0006009A FR2808689B1 (fr) 2000-05-11 2000-05-11 Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
EP01934089A EP1280541B2 (fr) 2000-05-11 2001-05-11 Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement du syndrome de l'intestin irritable

Publications (1)

Publication Number Publication Date
CY1107467T1 true CY1107467T1 (el) 2012-12-19

Family

ID=8850107

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100815T CY1107467T1 (el) 2000-05-11 2006-06-19 Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων

Country Status (13)

Country Link
US (2) US7749494B2 (el)
EP (1) EP1280541B2 (el)
JP (1) JP5183848B2 (el)
AT (1) ATE322902T1 (el)
AU (2) AU6040001A (el)
CA (1) CA2411563C (el)
CY (1) CY1107467T1 (el)
DE (1) DE60118723T3 (el)
DK (1) DK1280541T4 (el)
ES (1) ES2262650T5 (el)
FR (1) FR2808689B1 (el)
PT (1) PT1280541E (el)
WO (1) WO2001085187A1 (el)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
JP4618970B2 (ja) * 2002-08-02 2011-01-26 マルホ株式会社 肛門圧低下外用剤
US7935334B2 (en) * 2005-07-07 2011-05-03 Imagilin Technologies, LLC Probiotics as alternative medicines against infectious diseases
US20060008511A1 (en) * 2004-07-08 2006-01-12 Jhy-Jhu Lin Probiotic products for pet applications
DE102006062250A1 (de) * 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
ES2395838T3 (es) 2007-12-21 2013-02-15 Compagnie Gervais Danone Método para disminuir el contorno abdominal administrando una bacteria del tipo Bifidobacterium
EP2130543A1 (en) 2008-06-05 2009-12-09 Compagnie Gervais Danone Method for decreasing borborygmi by administering a bifidobacterium bacteria
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性t細胞の増殖または集積を誘導する作用を有する組成物
NZ618935A (en) 2010-08-04 2014-03-28 Karma Medical Prod Co Ltd Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
HK1253538A1 (zh) * 2010-08-04 2019-06-21 Borody Thomas J 用於糞便菌群植入的組合物及其製備和使用方法
KR101805873B1 (ko) * 2011-08-03 2018-01-10 한화케미칼 주식회사 단당류 인산 또는 그 유도체로 표면이 개질된 친수성 나노입자, 그의 콜로이드 용액 및 그 용도
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP3978598B1 (en) 2011-12-01 2024-08-28 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
BR112014024159A2 (pt) 2012-03-29 2017-06-20 Therabiome Llc Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
WO2014197562A1 (en) 2013-06-05 2014-12-11 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited Severe bacteroid tethethioomycron and its use in reducing inflammation
JP6427278B2 (ja) 2014-12-23 2018-11-21 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited pirinポリペプチド及び免疫モジュレーション
CA2977593A1 (en) 2015-02-27 2016-09-01 White Dog Labs, Inc. Mixotrophic fermentation method for making acetone, isopropanol, butyric acid and other bioproducts, and mixtures thereof
CN114990099A (zh) 2015-05-11 2022-09-02 迈彼欧提克斯制药有限公司 用于使益生菌在使细菌于肠道中定植用途的固体颗粒上生长成益生菌生物膜的系统和方法
WO2016183577A1 (en) 2015-05-14 2016-11-17 Crestovo Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
ES2909456T3 (es) 2015-05-22 2022-05-06 Univ Arizona State Métodos para tratar el trastorno del espectro autista y síntomas asociados
WO2016201114A1 (en) 2015-06-09 2016-12-15 Rebiotix, Inc. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
SI3360559T1 (sl) 2015-06-15 2020-02-28 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN114984057A (zh) 2015-06-15 2022-09-02 4D制药研究有限公司 包含细菌菌株的组合物
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3209310B1 (en) 2015-11-20 2018-01-31 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
NZ745678A (en) 2016-03-04 2019-03-29 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
JP7198087B2 (ja) 2016-05-25 2022-12-28 マイバイオティクス ファーマ リミテッド 微生物叢療法のための組成物及び方法
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
GB201703548D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商4D製藥有限公司 包含細菌菌株之組合物
GB201703552D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
GB201621123D0 (en) * 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
AU2018272291A1 (en) * 2017-05-22 2020-01-16 4D Pharma Research Limited Compositions comprising bacterial strains
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
HUE052319T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
CN111107859B (zh) 2017-06-14 2022-04-29 4D制药研究有限公司 包含细菌菌株的组合物
ES2917415T3 (es) 2017-06-14 2022-07-08 4D Pharma Res Ltd Composiciones que comprenden una cepa bacteriana
CN111328284A (zh) 2017-08-07 2020-06-23 芬奇治疗公司 用于维持和恢复健康的肠道屏障的组合物和方法
TW202007400A (zh) 2018-06-19 2020-02-16 英商4D製藥研究有限公司 產品
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
WO2020016252A1 (en) 2018-07-16 2020-01-23 4D Pharma Research Limited Compositions comprising bacterial strains
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
TW202108153A (zh) 2019-05-10 2021-03-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
US20220331376A1 (en) * 2019-09-05 2022-10-20 White Dog Labs Mixotrophic probiotic compositions and uses thereof in the treatment of bloating
EP3839039A1 (en) 2019-12-16 2021-06-23 4D Pharma Research Limited Providing bacterial biomass with improved storage stability
TW202220639A (zh) 2020-08-06 2022-06-01 英商4D製藥有限公司 凍乾方法
WO2022112526A1 (en) 2020-11-26 2022-06-02 4D Pharma Leon, S.L.U. Process

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
AUPM823094A0 (en) 1994-09-16 1994-10-13 Goodman Fielder Limited Probiotic compositions
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
AUPN698495A0 (en) * 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
WO1997034591A1 (en) * 1996-03-20 1997-09-25 The University Of New South Wales Alteration of microbial populations in the gastrointestinal tract
SE511524C2 (sv) 1997-06-02 1999-10-11 Essum Ab Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier
DE19826928A1 (de) 1998-06-17 1999-12-23 Novartis Consumer Health Gmbh Arzneimittel, lebensfähige anaerobe Bakterien enthaltend, die die Sulfatreduktion sulfatreduzierender Bakterien hemmen
WO2000010581A1 (fr) * 1998-08-20 2000-03-02 Miyarisan Pharmaceutical Co., Ltd. Medicaments comprenant une combinaison d'une bacterie produisant de l'acide butyrique, et d'un constituant d'acide biliaire

Also Published As

Publication number Publication date
DE60118723D1 (de) 2006-05-24
ATE322902T1 (de) 2006-04-15
AU2001260400B2 (en) 2006-10-26
JP5183848B2 (ja) 2013-04-17
FR2808689A1 (fr) 2001-11-16
DE60118723T2 (de) 2006-12-28
JP2004501095A (ja) 2004-01-15
CA2411563A1 (fr) 2001-11-15
US20030147858A1 (en) 2003-08-07
WO2001085187A1 (fr) 2001-11-15
PT1280541E (pt) 2006-06-30
CA2411563C (fr) 2012-12-11
EP1280541B1 (fr) 2006-04-12
EP1280541B2 (fr) 2010-03-17
US7749494B2 (en) 2010-07-06
DK1280541T3 (da) 2006-07-17
EP1280541A1 (fr) 2003-02-05
FR2808689B1 (fr) 2004-09-03
AU6040001A (en) 2001-11-20
DE60118723T3 (de) 2010-09-30
ES2262650T3 (es) 2006-12-01
US20100316617A1 (en) 2010-12-16
DK1280541T4 (da) 2010-07-05
ES2262650T5 (es) 2010-06-28

Similar Documents

Publication Publication Date Title
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
NO20061736L (no) Krystallform av epotilon B
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
ATE413386T1 (de) Ppar-gamma modulatoren
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
ATE506959T1 (de) Verwendung von il-18 inhibitoren
NO20054668L (no) Aplidin for multippelt myelom-behandling
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
DK1294379T3 (da) En hidtil ukendt anvendelse af deferipron
ATE405294T1 (de) Gezielt eingesetzte agenzien zur nervenregeneration
DE60229867D1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
MXPA02012911A (es) Compuestos de rutenio (ii) para el uso en terapia del cancer.
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
DK1212072T3 (da) Farmaceutisk præparat omfattende eukalyptus- og orangeolie
ATE241640T1 (de) Fusidinsäure-derivate
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE